Group 1 - Hyatt Hotels shares increased by 4.1% to $145.39 in the last trading session, with a notable trading volume, contributing to a 7% gain over the past four weeks [1] - The recent stock rally is attributed to investor optimism regarding Hyatt's asset-light strategy and luxury-led portfolio growth, including the introduction of the Hyatt Select brand and upper midscale expansion [2] - Progress on $2 billion in asset sales, including the Playa deal, enhances capital flexibility and boosts confidence in sustained performance [2] Group 2 - The upcoming quarterly earnings report is expected to show earnings of $0.62 per share, reflecting a year-over-year decline of 59.5%, while revenues are projected to be $1.74 billion, a 1.9% increase from the previous year [3] - The consensus EPS estimate for Hyatt has been revised 2.1% higher in the last 30 days, indicating a positive trend that typically correlates with price appreciation [4] - Hyatt Hotels currently holds a Zacks Rank of 3 (Hold), while another industry stock, Civeo, has a Zacks Rank of 2 (Buy) [5][6]

Core Viewpoint - Analysts expect TD SYNNEX to report quarterly earnings of $2.69 per share, reflecting a year-over-year decline of 1.5%, with revenues projected at $14.32 billion, an increase of 2.7% from the previous year [1] Earnings Estimates - There has been a 1% upward revision in the consensus EPS estimate over the last 30 days, indicating analysts' reassessment of their initial forecasts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Forecasts - Analysts estimate 'Revenue- Americas' to reach $8.74 billion, representing a 2.2% increase from the prior year [4] - 'Revenue- Europe' is expected to be $4.54 billion, indicating a 2.6% year-over-year change [4] - 'Revenue- Asia-Pacific and Japan' is projected at $1.03 billion, reflecting a year-over-year increase of 6.4% [4] Stock Performance - TD SYNNEX shares have returned +1.3% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [5] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [5]

Core Viewpoint - Analysts project that Commercial Metals (CMC) will report quarterly earnings of $0.75 per share, reflecting a 26.5% decline year over year, with revenues expected to reach $2.01 billion, down 3.3% from the same quarter last year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 5.1%, indicating a collective reassessment by covering analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts estimate that 'Net Sales- Emerging Businesses Group- Net sales from external customers' will be $185.76 million, a year-over-year decline of 1.5% [5]. - 'Net sales from external customers- North America' are projected to be $1.60 billion, reflecting a year-over-year decrease of 4.5% [5]. - 'Net sales from external customers- Europe' are expected to reach $215.88 million, indicating a year-over-year increase of 3.4% [6]. - 'Net sales from external customers- Corporate and Other' are estimated at $13.13 million, showing a significant year-over-year increase of 34.9% [6]. Key Metrics - The consensus estimate for 'Major product- North America- Other' is $37.24 million, reflecting a year-over-year increase of 18.4% [7]. - The average selling price (per ton) for 'Raw materials' in North America is forecasted to be $951.15, down from $970 in the same quarter last year [7]. - The estimated 'Steel products metal margin per ton' in Europe is projected at $289.43, slightly down from $292 year-over-year [7]. - The average selling price (per ton) for 'Downstream products' in North America is expected to be $1,252.19, down from $1,330 in the same quarter last year [8]. - The 'Steel products metal margin per ton' in North America is projected to be $495.12, down from $538 in the same quarter last year [9]. - 'Europe - Steel products (External tons shipped)' is expected to reach 317.31 thousand, up from 297 thousand year-over-year [9]. - The average prediction for 'Europe - Steel products - Rebar' is 97.15 thousand, up from 80 thousand in the same quarter last year [10]. Stock Performance - Over the past month, Commercial Metals shares have recorded a return of +0.8%, compared to the Zacks S&P 500 composite's +1.4% change, indicating potential underperformance in the upcoming period [11].

Monopar Therapeutics Inc. (MNPR) closed the last trading session at $34.51, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $52.20 indicates a 51.3% upside potential.The average comprises five short-term price targets ranging from a low of $37 to a high of $76, with a standard deviation of $15.69. While the lowest estimate indicates an increase of 7.2% from the current p ...

Amneal Pharmaceuticals (AMRX) closed the last trading session at $7.45, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11.50 indicates a 54.4% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.58. While the lowest estimate of $11 indicates a 47.7% increase from the current price level, the most optimistic analy ...

Core Viewpoint - Vertical Aerospace Ltd. (EVTL) has shown a significant price increase of 32% over the past four weeks, with a mean price target of $10.30 indicating a potential upside of 93.6% from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price targets for EVTL range from a low of $2 to a high of $15, with a standard deviation of $5.14, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 62.4%, while the highest points to an upside of 182% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding EVTL's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 100%, with two estimates moving higher and no negative revisions [12] - EVTL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - European Wax Center, Inc. (EWCZ) has shown a significant price increase of 51.5% over the past four weeks, with a mean price target of $6.50 indicating a potential upside of 27.7% from the current trading price of $5.09 [1] Price Targets and Analyst Consensus - The average price targets for EWCZ range from a low of $4 to a high of $15, with a standard deviation of $3.51, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 21.4%, while the most optimistic estimate indicates a potential upside of 194.7% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising EWCZ's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 127.1%, with four estimates moving higher and no negative revisions [12] - EWCZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][10] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8]

Core Insights - Analysts project that DocuSign (DOCU) will report quarterly earnings of $0.81 per share, reflecting a year-over-year decline of 1.2% [1] - Revenue is expected to reach $746.98 million, marking a 5.3% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Revenue Estimates - Analysts estimate 'Revenue- Professional services and other' at $16.09 million, indicating a decline of 11.4% from the prior-year quarter [4] - 'Revenue- Subscription' is projected to reach $730.77 million, reflecting a growth of 5.7% from the prior-year quarter [4] Key Metrics - 'Non-GAAP billings' are expected to arrive at $746.34 million, compared to $709.54 million reported in the same quarter last year [5] - The total number of customers is projected to reach 1.69 million, up from 1.5 million a year ago [5] - 'Enterprise & Commercial Customers' are forecasted to reach 268.32 thousand, an increase from 248 thousand in the previous year [5] Profitability Metrics - 'Non-GAAP subscription gross profit' is estimated to be $605.46 million, compared to $581.92 million from the previous year [6] Stock Performance - Shares of DocuSign have increased by 7.9% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 6.1% [6] - DocuSign holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [6]

Group 1 - Xperi (XPER) has shown a 7.3% increase in stock price over the past four weeks, with a mean price target of $18.25 indicating a potential upside of 134.3% [1] - The mean estimate includes four short-term price targets with a standard deviation of $8.02, suggesting variability in analyst predictions; the lowest estimate of $12 indicates a 54% increase, while the highest estimate suggests a 285.1% increase to $30 [2] - Analysts show strong agreement on XPER's ability to report better earnings than previously predicted, which supports the view of potential upside [4] Group 2 - The Zacks Consensus Estimate for XPER has increased by 46.2% over the past month, with no negative revisions, indicating positive earnings momentum [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which is a strong indicator of potential upside [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [13]

Core Viewpoint - Spyre Therapeutics (SYRE) shows significant upside potential with a mean price target of $53.50, indicating a 244.1% increase from its current price of $15.55 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $16.36, suggesting variability among analysts [2] - The lowest estimate of $21 indicates a 35.1% increase, while the highest estimate predicts a surge of 356.6% to $71 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about SYRE's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 5.7% over the past month, with two estimates rising and no negative revisions [12] - SYRE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]